


Company Profile

Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. Eiger's pipeline includes preclinical new chemical entities (NCEs) from its discovery shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses.

The lead program is an NS4B-RNA binding inhibitor, a newly identified target located on the HCV genome. Preclinical and clinical studies have demonstrated that NS4B-RNA interaction is required for HCV replication and that pharmacologic inhibition of this interaction may lead to an important therapeutic for HCV. Eiger is developing clemizole as well as multiple analogs as pharmacologic agents shown to inhibit NS4B-RNA.





Management

David Cory, RPh, MBA
President and Chief Executive Officer

Jeffrey Glenn, MD, PhD
Scientific Founder

Kevin Kaster, JD
Vice President of Patents and
Licensing

Keith Vendola, MD, MBA
Vice President of Finance

Wenjin Yang, PhD
Vice President of Chemistry

Board of Directors

David Cory, RPh, MBA
President and Chief Executive Officer,
Eiger BioPharmaceuticals

Edgar Engleman, MD
Managing Partner, Vivo Ventures

Jeffrey Glenn, MD, PhD
Scientific Founder, Associate
Professor, Stanford University

Nina Kjellson
General Partner, InterWest Partners

Paul Truex, MBA
President and Chief Executive Officer,
Anthera Pharmaceuticals

Key Activity and Upcoming Milestones

- Series A Financing of \$7.8MM in December 2008
- Stanford License signed in July 2009
- Eiger is conducting a Phase Ib Proof of Concept study investigating the efficacy with clemizole mono-therapy in treatment naïve HCV patients
 - Clinical Sites: Christchurch, New Zealand and Melbourne, Australia
 - Data is expected in 4Q 2009

Eiger BioPharmaceuticals, Inc.
3350 W Bayshore Road, Suite 120
Palo Alto, CA 94303
Phone: (650) 320-9900
Fax: (650) 320-9901
www.eigerbio.com